Stentys' IPO: European Public Markets Opening For Device Companies?
This article was originally published in Start Up
The emerging device companies that have been hardest hit by the economic woes of the past couple of years have been those looking for later-stage financing. These companies face venture investors who are either unwilling or unable to invest in late-stage deals, while also confronting an IPO market that largely remains closed to them, particularly in the US. In Europe, however, that may be changing, most notably in France, where Stentys SAS, which is developing stents to treat acute myocardial infarctions, recently became the second device company to successfully go public this year.
You may also be interested in...
Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.
Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.
In the fourth quarter, medical device companies raised $1.1 billion, a third of which was represented by follow-on public offerings. Acquisitions were strong overall, holding steady with 15 transactions - the same as Q3 - but only slightly less in money paid, $6 billion. In vitro diagnostic/research companies, like medical device, also ended 2010 on a high note, with funding totaling $511 million in Q4. The majority of the money spent on IVD/research acquisitions came from Thermo Fisher Scientific's buy of Dionex for $2.1 billion.